Cadence Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Cadence Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-103,341	Closed	-$1.13M	–	466
2018 Q4	$1.13M	Buy	103,341 +7,997	+8%	+$84.3K	0.11%	252
2018 Q3	$1.21M	Buy	+95,344	New	+$1.15M	0.07%	369

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cadence Capital Management's CCXI Position: Q1 2019 in Review

Cadence Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q1 2019, closing a stake of 103,341 shares — an estimated $1.13M sold.

Cadence Capital Management first reported a position in CCXI in Q3 2018 and held it in 2 quarters. The position peaked at $1.21M in Q3 2018. 117 funds tracked by Wall St. Rank hold CCXI as of Q1 2019.

Cadence Capital Management reported no remaining ChemoCentryx, Inc. position as of Q1 2019 after selling out during the quarter.
Cadence Capital Management sold 103,341 ChemoCentryx, Inc. shares in Q1 2019, an estimated $1.13M.
Cadence Capital Management first reported a position in ChemoCentryx, Inc. in Q3 2018 and held it in 2 quarters.
Cadence Capital Management's ChemoCentryx, Inc. position peaked at $1.21M in Q3 2018.
117 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q1 2019.

Based on Cadence Capital Management's 13F filing for Q1 2019, filed 7 May 2019.